AstraZeneca Wins With Concentration On Rural China
This article was originally published in PharmAsia News
U.K.-based AstraZeneca has developed a different China strategy than most of its global competitors in the drug-making business. Instead of concentrating on a quest for big sales in the largest of China's cities, AstraZeneca has been working on sales in more rural parts of the country ignored by competitors. The firm's sales in China about quintupled since 2001, with sales last year amounting to $423 million, making it No. 1 in the Chinese market. That domination could add leverage for AstraZeneca as it seeks to expand its share of the lucrative Chinese market. (Click here for more - a subscription may be required
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.